Floatz logo

m3814

Advanced Solid Tumors

Telix Pharmaceuticals (Innovations) Pty LimitedPhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
59/ 100

Competitive context

435 Active assets in the Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4BB
FLUOROURACILUM
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
InSilico Medicine Hong Kong Limited
Phase 4BB
Calcium folinate pentahydrate
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

m3814 is also rated in:

Unresectable Malignant Solid NeoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
Locally Advanced Unresectable Gallbladder CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Locally Advanced Unresectable CholangiocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →